Insiders who reported open-market trades in the last 12 months at the companies Helen Louise Collins files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
ORBIMED ADVISORS LLC - $51.68M in ELVN purchases and sales in the last 12 months
Mika K. Derynck - $9.56M in ELVN purchases and sales in the last 12 months
Helen Louise Collins is a corporate insider, tracked as CHIEF MEDICAL OFFICER of Enliven Therapeutics, Inc. (ELVN). InsiderAlpha holds 13 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Helen Louise Collins submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Helen Louise Collins been buying or selling stock?
Recorded transactions: 0 open-market purchases and 25 open-market sales ($5.41M) across all tracked filings.
Helen Louise Collins is CHIEF MEDICAL OFFICER of Enliven Therapeutics, Inc. (ELVN). 13 SEC Form 4 filings on record going back to 2024, most recently on 21 September 2026. Most recent open-market trade: sold $12K of ELVN on 21 September 2026. Lifetime open-market sales: $5.41M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Helen Louise Collins.
InsiderAlpha's records for Helen Louise Collins go back to 2024: 13 primary Form 4 filings, an average of 4.3 per year. 49 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
